Archives

Bain Capital Announces Sale of Newmarket Yards Residential Development in Dublin

BainCapital

DUBLIN – April 22, 2026 – Bain Capital, a leading global private investment firm, today announced the sale of Newmarket Yards, a fully leased residential development located in Dublin’s city center.

Completed in 2024, Newmarket Yards comprises 413 PRS apartments alongside a 151 key hotel which was pre-leased to Whitbread plc (t/a Premier Inn) and sold in 2023, ground-floor commercial space and a wide range of shared amenities, located in one of Dublin’s most dynamic and supply-constrained neighborhoods.

The transaction follows a multi-year investment during which Bain Capital, in partnership with Carrowmore Property, delivered a high-quality residential scheme designed to meet evolving tenant expectations for modern urban living. The project progressed from development through lease-up, reaching full occupancy in a relatively short period following completion, supported by strong demand for centrally located rental housing.

Situated within walking distance of Dublin’s central business district and key cultural landmarks, Newmarket Yards benefits from strong connectivity and access to major employment hubs. The development includes extensive amenities such as co-working spaces, wellness facilities, rooftop terraces, and community areas designed to support a range of lifestyles.

A central focus of the development was sustainability and long-term performance. The building achieved BREEAM “Excellent” certification and an A-rated energy standard, incorporating energy-efficient systems, low-carbon construction materials, and design features aimed at reducing operational impact while enhancing resident experience.

“This transaction highlights our ability to deliver large-scale residential developments through close partnership and disciplined execution,” said David Cullen, a Partner at Bain Capital. “Newmarket Yards reflects a focus on quality, sustainability, and design, alongside a strong understanding of local demand.”

“Newmarket Yards demonstrates the strength of our residential platform in Europe,” said John Kane, an Executive Vice President in Bain Capital’s Portfolio Group. “From initial development through leasing and delivery, this project reflects a hands-on approach to creating high-quality assets that are built to perform over the long term.”

The investment forms part of Bain Capital’s Europe Real Estate strategy, which focuses on developing and repositioning assets across living, logistics, hospitality, and digital infrastructure sectors in markets where demand remains strong and supply is constrained.

Financial terms of the transaction were not disclosed.

ENDS

About Bain Capital

Founded in 1984, Bain Capital is one of the world’s leading private investment firms. We are committed to creating lasting impact for our investors, portfolio companies, and the communities in which we live. As a private partnership, we lead with conviction and a culture of collaboration, advantages that enable us to innovate investment approaches, unlock opportunities, and create exceptional outcomes. Our global platform invests across five focus areas: Private Equity, Growth & Venture, Capital Solutions, Credit & Capital Markets, and Real Assets. In these focus areas, we bring deep sector expertise and wide-ranging capabilities. We have 24 offices on four continents, more than 1,900 employees, and approximately $225 billion in assets under management. To learn more, visit www.baincapital.com. Follow @BainCapital on LinkedIn and X (Twitter).

Media Contacts

Europe

 Jason Lobo

Categories: News

Tags:

Ardian announces the sale of its stake in TRIGO to Montyon Capital

No Comments
Ardian

Ardian, a global private investment firm, announces the sale of its stake in TRIGO, the global leader of quality management in the transportation sector, to Montyon Capital, a French investment fund.

Founded in 1997, TRIGO is a leading provider of inspection, quality engineering, and industrial performance management services, serving major players in the automotive, aerospace, rail, and other transportation industries.

With a presence in more than 25 countries and operations at hundreds of sites worldwide, the group has established itself as a key partner to manufacturers for the improvement of their production processes and quality. The company has more than 12,000 employees in Europe, the Americas, Asia, and North Africa.

Since acquiring a stake in 2016, Ardian has supported TRIGO’s extensive diversification, aimed at strengthening its position as a global platform for value-added quality services.

During this period, and in particular through 12 acquisitions in the United States and Europe, TRIGO has significantly expanded:
•    Its geographic footprint through international expansion — particularly in North America — with a presence now spanning nearly 30 countries;
•    Its end-market exposure, by extending its strong expertise in the automotive sector to aerospace, rail, defense, and heavy transportation;
•    Its service offering, with a shift toward activities such as quality engineering, analysis, auditing, and training.

This transformation has strengthened TRIGO’s position as a global one-stop-shop platform for quality services in the manufacturing industry, enhancing its ability to address its clients’ most critical challenges across international and increasingly complex supply chains.

The group has also demonstrated the strong resilience of its business model, having successfully navigated several economic cycles and major crises that have significantly impacted the transportation sector, while maintaining solid operational performance and a sustainable growth trajectory.

Montyon Capital’s investment marks the start of a new phase of growth for the group, building on the strength of its management team led by Matthieu Rambaud and Benoit Leblanc and on the solid foundation established over the past decade.

“Since our investment, TRIGO has undergone a profound transformation in terms of geographic reach, end-market exposure, and operating model. The group has significantly strengthened its market position, developed engineering and auditing services, and demonstrated remarkable resilience in a complex environment. We would like to extend our heartfelt thanks to Matthieu Rambaud, Benoit Leblanc, and their entire team for their dedication and the outstanding work they have accomplished alongside us.” Edouard Level, Managing Director Buyout, Ardian.

“We are very proud of the journey we have taken with Ardian, which has supported us with high standards and ambition to make TRIGO the global leader we are today. This new phase with Montyon Capital builds on that momentum. Their knowledge of our industry, their partnership-based approach, and their belief in TRIGO’s potential make them the ideal shareholder to support the next phase of our growth. Together with our teams, we are approaching this new phase with enthusiasm and determination.” Matthieu Rambaud and Benoit Leblanc, CEO, TRIGO.

The completion of the transaction remains subject to the clearance from the relevant competition authorities.

List of participants

  • Ardian

    • Ardian: Edouard Level, Edmond Delamalle, Martin Blanc
    • Ardian financing team: Gregory Buscayret, Aris Toranian
    • M&A advisors: Baird
    • Legal advisor: Latham & Watkins
    • Strategic DD: BCG
    • Financial DD: EY
    • Legal, social & tax DD: EY

ABOUT ARDIAN

In a world of constant evolution, Ardian stands out for its ability to anticipate, adapt, and turn challenges into opportunities. As a global, diversified private markets firm with 22 offices and more than 350 investment professionals worldwide, we provide investment and customized solutions that reflect new economic dynamics and help our clients remain resilient in a changing world.
We deliver multi-local expertise and long-term performance for our investors and partners as well as shared value for the broader society. Since Ardian’s inception in 1996, our pioneering approach to diversification and our ability to offer tailor-made solutions at scale have remained the heart of our strategy.
Through commitment, knowledge and technology, we bring lasting value to our companies and contribute positively to the whole industry.
Ardian currently manages or advises $200bn for more than 1,920 clients worldwide across Private Equity, Real Assets, and Credit.
Ardian. Mastering change for lasting value.

ardian.com

ABOUT TRIGO

TRIGO is a global provider of comprehensive quality management solutions for the transportation sector. Founded in 1997, the group supports leading manufacturers, particularly in the automotive, aerospace, defense, rail, and heavy transportation industries, optimizing their quality performance throughout the value chain.
With a presence in more than 25 countries across Europe, the Americas, and Asia, TRIGO operates at several hundred sites and draws on recognized expertise in various services from inspecting and reworking components, to testing, auditing, consulting, training, and engineering.

trigo-group.com

MEDIA CONTACTS

ARDIAN

HEADLAND

ardian@headlandconsultancy.com

Categories: News

Tags:

ALTÉRRA Commits to KKR’s Global Climate Transition Strategy to Accelerate Investment in Real-Economy Infrastructure

No Comments
KKR

Reinforces ALTÉRRA’s strategy to mobilize capital at scale through global partnerships accelerating the climate transition

Abu Dhabi, 21 April 2026 – ALTÉRRA today announced a commitment from its Acceleration Fund to KKR’s Global Climate Transition Strategy, further expanding its portfolio of strategic partnerships through an effort focused on accelerating climate and energy transition investments across North America, Europe, and Asia.

imgFrom left to right: His Excellency Majid Al Suwaidi, CEO of ALTÉRRA; Scott Nuttall, Co-Chief Executive Officer of KKR.

KKR’s Global Climate Transition Strategy invests in climate solutions that endeavor to enable efficiency, security and decarbonization for society across all sectors of the physical economy. This includes assets that are central to the functioning of the economy, spanning sectors such as renewables and storage, electrification, energy efficiency, sustainable fuels, waste, and circular economy solutions.

Demand for infrastructure across electrification, grid resilience, and industrial decarbonization is accelerating, driven by rising energy demand, energy security priorities, and the increasing cost competitiveness of clean technologies. As adoption scales and capital shifts toward climate-aligned assets, a clear opportunity is emerging to invest at scale in the systems that will power resilient, low-carbon economies and underpin long-term growth.

Karim Radwan, Partner and Head of Investments at ALTÉRRA, commented: “Our strategic partnership with KKR reflects ALTÉRRA’s commitment to investing in real assets that can accelerate decarbonization, while demonstrating that impact and commercial performance can go hand in hand. As global economies expand clean power capacity, modernize grids and electrify transport and industry, the need for large-scale, resilient infrastructure will continue to grow. Against this backdrop, we need to direct capital at scale into solutions that will enable the next phase of the global climate transition.”

Charlie Gailliot and Emmanuel Lagarrigue, Co-Heads of KKR’s Global Climate Transition Strategy said: “We are delighted to collaborate with ALTÉRRA on our Global Climate Transition strategy, which reflects a shared commitment to accelerating investment in the infrastructure underpinning the energy transition. As energy demand continues to grow, we see a significant opportunity to invest in solutions that enhance energy security, improve affordability, and ensure reliability, while supporting decarbonization across the real economy. By combining ALTÉRRA’s global perspective with KKR’s experience investing across climate and infrastructure, we are well positioned to scale proven technologies and build more resilient, efficient energy systems for the long term.”

KKR’s Global Climate Transition strategy has made seven investments since launch, including Zenobē, a UK-based transport electrification and battery storage solutions specialist; EGC, an energy service provider in Germany; Dawsongroup, an independent asset leasing business which provides a diverse range of business-critical solutions; Avantus, a solar and solar-plus-storage developer in the US; IGNIS P2X, an industrial decarbonisation platform; CleanPeak Energy, a leading provider of integrated solar and storage systems; and HMC Capital’s energy transition platform.

KKR brings more than 15 years of experience in global infrastructure investing, with US$100 billion in infrastructure assets under management. Since 2011, the firm has invested more than US$44 billion in climate and environmental sustainability investments.

Since launch, ALTÉRRA has supported a growing portfolio of climate-focused investments and strategic partnerships globally. Its commitment to the KKR Global Climate Transition Strategy further expands this portfolio, reinforcing ALTÉRRA’s role in mobilizing capital into the infrastructure and solutions shaping the next phase of the global climate transition.

– ENDS –

About ALTÉRRA
ALTÉRRA is one of the world’s largest private investment vehicles for climate finance. Launched at COP28 with a US$30 billion commitment from the UAE, ALTÉRRA aims to build innovative partnerships to mobilize US$250 billion globally by 2030 to finance the new climate economy and accelerate the climate transition.

ALTÉRRA operates three funds. The Acceleration Fund directs capital towards projects crucial for accelerating the global transition to a net-zero and climate-resilient economy at scale. The Transformation Fund incentivizes investment flows in high-growth climate opportunities in underserved markets by providing catalytic capital. The Opportunity Fund is a climate co-investment vehicle, pursuing a diversified global investment strategy across climate-aligned infrastructure, private equity and private credit.

Altérra Management Limited is duly licensed and authorized by the ADGM Financial Services Regulatory Authority under the Financial Services Permission No. 200001.

 

Download PDF

Categories: News

Tags:

McKesson Signs Agreement with Apollo Funds for Strategic Minority Interest in Medical-Surgical Solutions

Apollo logo

IRVING, Texas, April 20, 2026 – McKesson Corporation (NYSE: MCK), a leading Healthcare Services company, today announced it has entered into a definitive agreement with funds managed by affiliates of Apollo (“Apollo Funds”), under which Apollo Funds will acquire a minority ownership interest in McKesson’s Medical-Surgical Solutions (“MMS”) business. This transaction represents a meaningful milestone as McKesson executes its separation strategy of MMS in preparation of a planned initial public offering.

Apollo Funds will invest $1.25 billion in convertible preferred equity of MMS to acquire an approximately 13% minority interest in MMS. The transaction values MMS at approximately $13 billion total enterprise valuation. McKesson will retain operating control and majority ownership of MMS and consolidate the results for financial reporting. The transaction is subject to regulatory approvals and customary closing conditions.

“This transaction marks a key milestone in McKesson’s planned separation of MMS,” said Brian Tyler, chief executive officer of McKesson. “We are pleased to welcome Apollo as an important strategic and financial partner. Apollo’s experience in supporting complex carve-out and public market transactions will be additive as we position MMS for success, while maintaining McKesson’s financial and strategic flexibility. We look forward to working together to execute the separation in a manner that maximizes shareholder value, and establishing a well-capitalized, world-class medical surgical supply and solutions company.”

“MMS is a leading healthcare platform with a talented team and strong market position, playing a key role in healthcare supply chain resiliency across non-acute care settings,” said Apollo Partner Maxwell David and Managing Director Jeff Armstrong. “We believe the business is well positioned for continued growth, and that Apollo’s Hybrid platform enables us to provide flexible, scaled capital to support the next phase of development as MMS prepares to operate as a standalone company.”

Cautionary Statements

Statements in this press release about of the anticipated completion of Apollo’s investment in MMS, McKesson’s intent to separate MMS into an independent company, the planned initial public offering (“IPO”) of MMS, and the expected benefits of the transactions described, including anticipated timing, plans, expectations, commitments and intentions, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Readers should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly update forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Although it is not possible to predict or identify all such risks and uncertainties, risk factors include, but are not limited to: Apollo’s investment and the planned separation and IPO of MMS are contingent upon the satisfaction of certain conditions, may not be completed on the currently contemplated terms or timeline, or at all, and, if completed, may not achieve the intended financial and strategic benefits; unanticipated business, market, governmental, or other developments could delay or prevent completion of Apollo’s investment, the separation, or the IPO, or cause any of the transactions to occur on less favorable terms; the transactions described are subject to conditions that may not be satisfied on the expected timeline, or at all, which could delay or prevent closing; we may be unsuccessful in achieving our strategic growth objectives; we might be adversely impacted by changes in the economic environments in which we operate; and we might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events, and other catastrophic events. We encourage investors to read the important risk factors described in McKesson’s most recent Form 10-K filed with the Securities and Exchange Commission.

About McKesson Corporation

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Stories & Insights.

About Apollo

Apollo is a high-growth, global alternative asset manager. Apollo’s asset management business  seeks to provide its clients excess return at every point along the risk-reward spectrum from investment grade credit to private equity. For more than three decades, Apollo’s investing expertise across its fully integrated platform has served the financial return needs of its clients and provided businesses with innovative capital solutions for growth. Athene, Apollo’s retirement services business, specializes in helping clients achieve financial security by providing a suite of retirement savings products and acting as a solutions provider to institutions. Apollo’s patient, creative, and knowledgeable approach to investing aligns its clients, the businesses it invests in, its employees, and the communities it impacts, to expand opportunity and achieve positive outcomes. As of December 31, 2025, Apollo had approximately $938 billion of assets under management. To learn more, please visit www.apollo.com

Contacts

McKesson Corporation

Investors
Investors@McKesson.com

Media Relations
MediaRelations@McKesson.com

Apollo

Noah Gunn
Global Head of Investor Relations
Apollo Global Management, Inc.
(212) 822-0540
IR@apollo.com

Joanna Rose
Global Head of Corporate Communications
Apollo Global Management, Inc.
(212) 822-0491
Communications@apollo.com

Categories: News

Tags:

Bain Capital Announces Sale of Severo 246 in Rome Following Full Repositioning

BainCapital

LONDON and ROME — April 20, 2026 – Bain Capital, a leading global private investment firm, today announced the sale of Severo 246, a fully repositioned office building located on Via Cristoforo Colombo in Rome.

The transaction marks the successful execution of a multi-year asset transformation strategy, under which Bain Capital repositioned a legacy single-tenant office into a modern, high-quality workspace aligned with current occupier demand. Severo 246 comprises approximately 12,000 sqm of office space in the Greater EUR district, a well-established business area in the capital.

Following the departure of the incumbent tenant, the firm undertook a comprehensive refurbishment and leasing programme, including the redevelopment of internal layouts, upgrades to common areas, and the introduction of modern amenities. The building was subsequently fully pre-leased ahead of completion and delivered to a new occupier in 2025.

Severo 246 is located on Via Cristoforo Colombo, a major arterial route equidistant from Rome’s city centre and the EUR office district, and benefits from strong connectivity and proximity to a range of corporate occupiers.
“This transaction reflects our ability to identify underutilised assets and reposition them through hands-on execution,” said David Cullen, a Partner on Bain Capital’s Europe Real Estate team. “We acquired a single-tenant building with leasing risk and transformed it into a modern, fully leased asset aligned with tenant demand. It is a strong example of how we create value through disciplined asset management and local execution.”

“Severo 246 is representative of our broader approach in Europe, where we focus on situations that require operational expertise and capital investment to unlock value,” said Javier Ortigosa, an Operating Partner at Bain Capital. “From refurbishment through leasing and delivery, this was a full-cycle investment that demonstrates the strength of our platform.”

The investment formed part of Bain Capital’s Europe Real Estate strategy, which focuses on repositioning and developing high-quality assets across living, logistics, hospitality and office sectors in supply-constrained markets.

Financial terms of the transaction were not disclosed.
Advisors

JLL and Cushman & Wakefield act as sell side advisors to Savills Investment Management SGR and Bain Capital. Gatti Pavessi Bianchi Ludovici provided legal counsel on the transaction.

ENDS

About Bain Capital
Founded in 1984, Bain Capital is one of the world’s leading private investment firms. We are committed to creating lasting impact for our investors, portfolio companies, and the communities in which we live. As a private partnership, we lead with conviction and a culture of collaboration, advantages that enable us to innovate investment approaches, unlock opportunities, and create exceptional outcomes. Our global platform invests across five focus areas: Private Equity, Growth & Venture, Capital Solutions, Credit & Capital Markets, and Real Assets. In these focus areas, we bring deep sector expertise and wide-ranging capabilities. We have 24 offices on four continents, more than 1,900 employees, and approximately $225 billion in assets under management. To learn more, visit www.baincapital.com. Follow @BainCapital on LinkedIn and X (Twitter).

 

Categories: News

Tags:

IK Partners to acquire Selatek from Amplio

IK Partners

IK Partners (“IK”) is pleased to announce that the IK X Fund (“IK X”), has signed an agreement to invest in SELATEK Holding AB (“Selatek” or “the Group”), a leading Swedish technical installation platform. IK will succeed Amplio I, a fund advised and managed by Amplio Private Equity AB (“Amplio”), as lead investor. Financial details of the transaction are not disclosed and completion is subject to customary regulatory approvals.

Headquartered in Stockholm, Sweden, Selatek is a technical installation platform, specialising in Security, Electrical and Automation solutions across buildings, infrastructure and industrial environments, with a strong focus on security-sensitive operations. Established in 2022 following Amplio’s acquisition of Levinsgruppen in November 2021, the Group brings together several local technical service providers under a common structure.

Selatek operates a decentralised model, where its subsidiaries retain strong local brands and customer relationships, while benefiting from shared resources, technical expertise and centralised support functions at the Group level. Through close collaboration within regional clusters, Selatek is able to achieve a high degree of workforce flexibility and cross-sale opportunities. Operating across more than 30 locations in Southern and Central Sweden, the Group has over 900 full-time employees who serve a broad and loyal base of nearly 6,000 customers.

Under IK’s ownership, Selatek will continue to pursue organic growth in its core disciplines, with an increasing focus on more complex security, automation and electrical installations and a higher share of service revenues. The Group will also look to leverage IK’s extensive experience in executing strategic cross-border M&A to accelerate its expansion across the Nordics, while working in close partnership to drive operational improvements, including procurement and workforce planning.

Magnus Löfgren, Chief Executive Officer of Selatek, said: “We are excited to confirm the formation of this new partnership with IK. With their strong expertise in the Nordic Industrials sector, we see a clear opportunity to further accelerate our development — building on our proven model of combining entrepreneurial local companies with a structured platform for growth. Together, we will continue to drive value through targeted acquisitions, while further strengthening our operational performance, cross-business collaboration and efficiency across the Group. We would like to thank the team at Amplio for their strong support and partnership over the past few years. They have played an important role in shaping the platform we have today and we now look forward to taking the next step in our journey together with IK.”

Carl Jakobsson, Partner at IK and Advisor to the IK X Fund, commented: “In a time where security, electricity capacity and automation are crucial topics for society, Selatek has proven itself as a leading technical installation provider in the Nordics, with a differentiated positioning that has consistently outperformed the broader market. We are confident that the Group’s robust organic growth, attractive M&A pipeline and scope for operational improvements will support its continued development, while preserving the successful decentralised operating model that is so highly valued by its customers. We look forward to working alongside Magnus and his team to support this next phase of development.”

Marcus Planting-Bergloo, Managing Partner at Amplio, added: “It has been a privilege to support Selatek over the past four and a half years, during which the business has delivered strong growth. Throughout our partnership, the Group expanded its footprint across Sweden and strengthened its service offering and technical capabilities through a series of carefully selected acquisitions. Today, it is uniquely positioned as the only integrated end-to-end discipline specialist in the Swedish market and we are proud to have been part of that journey. We look forward to following Selatek’s continued success and wish Magnus, his team and IK all the very best in their new partnership.”

For further questions, please contact:

Selatek
Magnus Löfgren, Chief Executive Officer
Phone: +44 (0)702 096 614
magnus.lofgren@selatek.se

IK Partners
Vidya Verlkumar, Director of Communications and Marketing
Phone: +44 (0)7787 558 193
vidya.verlkumar@ikpartners.com

Amplio Private Equity
Marcus Planting-Bergloo, Managing Partner
Phone: +46 (0)702 291 185
planting@amplio.se

About IK Partners

IK Partners (“IK”) is a European private equity firm focused on investments in the Benelux, DACH, France, Nordics and the UK. Since 1989, IK has raised more than €20 billion of capital and invested in over 210 European companies. IK supports companies with strong underlying potential, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects. For more information, visit ikpartners.com IK is an affiliate of Wendel. For more information, visit wendelgroup.com

Read More 

About Amplio Private Equity

Established in 2024 by the former Segulah team, Amplio is a Swedish private equity firm specialising in the Nordic lower mid-market with a strong track record and long experience of developing companies in close cooperation with skilled entrepreneurs, business leaders and industrial experts. Amplio has a distinct sector focus on Business Services and IT & Technology Services, combined with strong buy-and-build focus. To ensure long term structural growth we invest, with sustainability in focus, into markets fuelled by three major themes: ‘Sustainable Solutions’, ‘Digital Business Efficiency’ and ‘Smart Urbanisation’. For more information, visit amplio.se

Read More 

Categories: News

Tags:

Eurobio Scientific signs definitive agreement to acquire CareDx’s transplant lab production division

IK Partners

Acquisition of CareDx’s ‘lab products’ portfolio creates new opportunities for growth and innovation in the fast growing transplant diagnostics market 

  • Acceleration of Eurobio’s strategic plan to become an in-vitro molecular diagnostics (“IVD”) leader
  • Creation of a global leading provider of kits for transplantation genomics
  • Acquisition of a 100% proprietary products portfolio
  • Deeper capabilities and larger scale with technological and commercial complementarities

Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in-vitro medical diagnostics for transplantation, oncology and infectious diseases, today announces that it has entered into a definitive agreement to acquire the Lab Products division of CareDx, a US global precision medicine company focused on transplantation.

Through the acquisition of CareDx’s Lab Products division, the transaction brings together two highly complementary portfolios in human leukocyte antigen (“HLA”) typing and transplantation diagnostics. It combines Eurobio Scientific affiliate GenDx’s expertise in next-generation sequencing (“NGS”) assays, software and global commercial footprint, with CareDx’s portfolio of HLA-typing and transplant monitoring kits as well as its market leading customer service.

Strategic Rationale

This acquisition enables GenDx to offer a more comprehensive portfolio across the transplantation IVD workflow, from pre-transplant HLA typing to post-transplant monitoring solutions. The combined entity will offer an expanded portfolio of molecular assays, reagents, and software, with the aim of enabling laboratories to streamline operations and improve clinical outcomes.

The integration of CareDx’s LabProducts division strengthens GenDx’s presence in key markets, including the United States, Europe and Asia-Pacific, while enhancing its ability to serve both research and clinical laboratories.

Key Highlights

  • Expanded Product Portfolio: Integration of CareDx’s HLA typing kits, including real-time polymerase chain reaction (“PCR”) and NGS-based solutions, with GenDx’s NGS assays and software platforms
  • Global Commercial Scale: Enhanced distribution capabilities and customer access across major transplantation markets
  • Technology Synergies: Acceleration of innovation in high-resolution HLA typing, hybrid capture, and transplantation monitoring workflows
  • Operational Efficiencies: Opportunities to streamline manufacturing and supply chain operations

Leadership Commentary

“This acquisition marks a significant milestone in our mission to advance precision medicine in transplantation,” said Denis Fortier, CEO of Eurobio Scientific. “By combining our technological leadership with CareDx’s strong Lab Products portfolio, we are uniquely positioned to deliver comprehensive solutions to transplant laboratories worldwide.”

John Hanna, CEO of CareDx, added: “This transaction allows us to further focus on our core strengths in U.S.‑based Precision Medicine Diagnostic Testing Services and Patient and Digital Solutions, while ensuring that our Lab Products business continues to thrive under Eurobio’s leadership.”

Transaction Details

The transaction is subject to customary closing conditions and regulatory approvals. Under the terms of the agreement, Eurobio Scientific will acquire CareDx’s Lab Products business in cash for an equivalent of €145 million ($170 million), subject to customary adjustments.

Following closing, the LabProducts division will be integrated into GenDx’s operations, with a focus on maintaining continuity for customers, partners, and employees.

Eurobio Scientific is represented by TD Cowen and Kahn Partners in this transaction.  CareDx is represented by Rothschild & Co. and Fenwick.

Contacts

Groupe Eurobio Scientific
Denis Fortier, Chairman and CEO
Olivier Bosc, Deputy CEO/ CFO Tel. +33(0) 1 69 79 64 80

Actus
Mathieu Calleux
Investors Relations Tel. +33(1) 53 65 68 68 – eurobio-scientific@actus.fr

About Eurobio Scientific

Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, oncology, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 290 employees and four production units based in the Paris region, in Germany, in the Netherlands and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany, Antwerp Belgium, Utrecht in The Netherlands and Milan in Italy. Eurobio Scientific’s reference shareholder is the Eurobio Development Holding company which brings together its two directors, Jean-Michel Carle and Denis Fortier, alongside IK Partners, “Pépites et Territoires” by AXA & NextStage AM investment program managed by NextStage AM as well as Jérome de Castrie. For more information, please visit: www.eurobio-scientific.com The company is publicly listed on the Euronext Growth market in Paris Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label. Symbol: ALERS – ISIN Code: FR0013240934 – Reuters: ALERS.PA – Bloomberg: ALERS:FP

Read More 

Categories: News

Tags:

KKR Appoints Rob Shuter as Executive Advisor to Support European Digital Infrastructure Investments

KKR

15 April 2026, London — KKR, a leading global investment firm, today announced the appointment of Rob Shuter as an Executive Advisor. In this role, Mr. Shuter will support KKR’s digital infrastructure investment activities across Europe, leveraging his extensive experience in digital infrastructure, enterprise solutions, and operational transformation.

“We are delighted to welcome Rob to KKR,” said Vincent Policard, Co-Head of European Infrastructure at KKR. “He brings a rare combination of operational leadership and deep sector expertise across telecoms and fibre networks. As demand for high-quality digital infrastructure continues to accelerate across Europe, Rob’s experience will further strengthen how we originate, underwrite and scale platforms critical to accelerating Europe’s digital economy.”

Mr. Shuter previously served as CEO of BT Enterprise from 2021 to 2023, where he led the division’s strategic repositioning and growth initiatives. Prior to joining BT, he was CEO of Vodafone’s Europe Cluster and Group President and CEO at MTN Group, where he drove significant expansion and digital transformation programmes.

In his advisory role, Mr. Shuter will work closely with KKR’s Infrastructure teams, providing strategic guidance on investment opportunities and supporting portfolio companies with operational expertise.

“I am thrilled to be joining the KKR team at this pivotal moment for digital infrastructure in Europe,” said Rob Shuter. “I look forward to working closely with the KKR team in both scaling their existing assets as well as expanding the portfolio.”

KKR established its global infrastructure strategy in 2008 and currently manages over $100 billion in infrastructure assets. The firm has extensive telecommunications experience, investing in leading FTTH providers globally with over 25 million homes passed and building more than four million annually. KKR’s portfolio includes fibre networks in the US, the UK, the Netherlands, Norway, Italy, Spain, Chile and Colombia.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

Media contact
Emma Black, KKR
media@kkr.com

 

Download PDF

Categories: People

Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

No Comments
BainCapital

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –

– Lead program afimetoran, a potential best-in-disease oral therapy for lupus, to complete Phase 2 trial in 2H 2026 before commencing pivotal development program –

– Saqib Islam, Chief Executive Officer, leads established executive team with proven track record in drug development and global commercialization of first- and best-in-class medicines –

– $300 million Series A financing led by Bain Capital supports operations into late-stage clinical development –

STAMFORD, Conn. and BOSTON – April 15, 2026 –  Beeline Medicines Corporation (“Beeline Medicines” or “the Company”), a clinical-stage biotechnology company, today announced its official debut with the mission of developing and delivering category-leading precision therapies to transform the lives of people with autoimmune and inflammatory diseases. Originally formed in July 2025, the Company’s initial portfolio is comprised of five programs in-licensed from Bristol Myers Squibb (NYSE: BMY, “BMS”), each of which is a mechanistically-guided, highly-selective therapeutic candidate with the potential to meaningfully improve the long-term health and outlook for patients living with a broad array of devastating immune-mediated conditions. With an established executive team and backed by a $300 million Series A financing led by Bain Capital, Beeline Medicines is poised to define the future of care for patients in need of life-changing treatments.

“Today marks an important milestone as Beeline Medicines debuts with a clear purpose: to deliver new, clinically significant treatment options for people living with autoimmune and inflammatory diseases,” said Saqib Islam, Chief Executive Officer of Beeline Medicines. “We are building a company with the scientific and operational rigor required to urgently deliver durable, transformative innovations to address the substantial unmet needs of this patient community. Our lead program, afimetoran, is a once-daily oral investigational therapy with the potential to change the treatment paradigm for lupus patients. As our Phase 2 trial nears completion, we are preparing for pivotal development of afimetoran, and we expect several additional clinical trials to start across our pipeline over the next 12 months.”

Differentiated Pipeline of Precision Therapies

Beeline Medicines is advancing a differentiated pipeline of precision therapies grounded in validated biology, powered by potential best-in-class molecular designs, and driven by an efficient clinical development strategy that prioritizes addressing high unmet patient needs. This mechanistically informed approach enables targeting of the underlying causes of immune-mediated diseases, restoration of immune balance, and the opportunity to dramatically improve outcomes for patients.

  • Afimetoran: Beeline Medicines’ lead program is a selective, small molecule, once-daily, equipotent TLR7/8 inhibitor that has the potential to be a best-in-disease oral therapy for lupus. Afimetoran established early clinical proof-of-concept in a Phase 1b study in cutaneous lupus erythematosus (CLE), and in May 2025 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of systemic lupus erythematosus (SLE). A Phase 2 study in SLE is ongoing and expected to complete in the second half of 2026, after which Beeline Medicines intends to commence its pivotal development program.
  • BMS-986326: A novel IL-2-CD25 fusion protein in Phase 1b development for atopic dermatitis and lupus (CLE and SLE); it is designed to address limitations of prior IL-2-directed therapies through improved selectivity for regulatory T cells (Treg) by slowly releasing IL-2 and providing pharmacokinetic (PK)/pharmacodynamic (PD) properties that drive potential for best-in-class Treg expansion and extended dosing intervals.
  • Lomedeucitinib (formerly BMS-986322): A potent, small molecule, once-daily, oral, allosteric TYK2 inhibitor that achieved positive proof-of-concept in a placebo-controlled Phase 2 study in plaque psoriasis, with potential for first-in-class development in rare immunological diseases.

Beeline Medicines’ emerging pipeline includes two IND-stage next-generation biologics with novel mechanisms focused on the IL-18 and IL-10 pathways, both validated approaches for addressing inflammation across multiple indications, including in gastrointestinal inflammatory conditions. The shared disease biology across the Company’s pipeline enables long-term, sustained growth through indication expansion, combination approaches, and business development.

“Immune-mediated diseases remain an area of profound need, and we believe that Beeline Medicines is positioned to redefine treatment across multiple underserved autoimmune and inflammatory conditions,” said Dr. Nathalie Franchimont, Chief Medical Officer of Beeline Medicines. “We believe afimetoran, our lead program in lupus, reflects the differentiated, patient-centered approach that we will bring to this field: a precision oral therapy designed to address the underlying drivers of lupus biology in a way that improves clinical outcomes and fits into patients’ lives. With three programs in the clinic and two additional candidates advancing toward first-in-human studies, we aim to move care beyond symptom management to immune system recalibration, durable disease control, and meaningful improvements for patients.”

Industry-Leading Management Team and Board of Directors

In conjunction with the official launch, Beeline Medicines announced its founding executive leadership team, bringing deep experience across autoimmune and inflammatory disease drug discovery and development, regulatory approvals, global commercialization, capital formation, and business and corporate development. Beeline Medicines’ executive team has contributed to the approval and launch of over a dozen medicines combined over their careers, impacting the lives of millions of people worldwide.

  • Saqib Islam, Chief Executive Officer
  • Badreddin Edris, Ph.D., President & Chief Operating Officer
  • Nathalie Franchimont, M.D., Ph.D., Chief Medical Officer
  • Kristin Patterson, Ph.D., Chief Technical Operations Officer
  • Daniel Pichl, Chief People Officer

Beeline Medicines has also assembled a seasoned Board of Directors spanning renowned R&D leaders, pharmaceutical executives, and life science investors to support the Company’s strategic direction and growth. The Board is chaired by Daniel S. Lynch, who has served alongside Robert Plenge, M.D., Ph.D., Nicholas Downing, M.D., Adam M. Koppel, M.D., Ph.D., and Andrew Kaplan since the closing of the Company’s Series A financing in July 2025. Saqib Islam, Chief Executive Officer of Beeline Medicines, also serves as a Board member. More recently, Martin Mackay, Ph.D., has joined the Board of Directors, bringing more than three decades of global R&D leadership experience, including executive roles at Pfizer, AstraZeneca, and Alexion Pharmaceuticals, and Board positions at Novo Nordisk, Charles River Labs, and Kailera Therapeutics.

“With a category-defining portfolio, world-class executive leadership team, and operational excellence, Beeline Medicines is positioned to deliver medicines that can change the lives of people with devastating immunological conditions,” said Mr. Lynch. “I look forward to supporting Beeline Medicines in building an impactful immunology company that develops these urgently needed therapies.”

About Beeline Medicines

Beeline Medicines is a clinical‑stage biotechnology company focused on developing and delivering category-leading precision therapies to transform the lives of people living with autoimmune and inflammatory diseases. With a portfolio of potential best-in-class and first-in-disease therapeutic candidates that directly target key pathways governing dysregulated immunological and inflammatory responses, the Company is developing medicines that have the opportunity to provide durable, life-changing impact. Led by an established executive team and backed by world-class life science investors, each day Beeline Medicines is determined to bring the scientific rigor and operational excellence to get to what matters for patients – realizing a world where people with immune-mediated diseases can live life fully.

For more information, visit www.BeelineMedicines.com and follow on LinkedIn.

Categories: News

Tags:

KKR and Samsung SDS Form Strategic Partnership to Drive Long-Term Value Creation

KKR

KKR to become active minority investor through KRW 1.22 trillion ($820 million) investment

SEOUL, South Korea–(BUSINESS WIRE)– KKR, a leading global investment firm, and Samsung SDS, a leading enterprise IT solutions company (the “Company”) and a member of Samsung Group, today announced a strategic partnership to support Samsung SDS’ next phase of growth and long-term value creation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414166241/en/

Under the strategic partnership, KKR, through funds managed by KKR, and Samsung SDS will closely collaborate on a range of value creation initiatives for the Company, including supporting organic and inorganic growth strategies, accelerating the Company’s expansion as a full‑stack AI solutions provider, and expanding into new business areas. KKR will also serve in an active advisory capacity to Samsung SDS’ management team, particularly in areas including M&A, capital allocation, and supporting the Company’s efforts to pursue strategic growth opportunities globally.

In connection with the strategic partnership, funds managed by KKR have entered into definitive agreements to acquire KRW 1.22 trillion ($820 million) of convertible bonds newly issued by Samsung SDS. The Company intends to utilize the investment, together with its existing resources, to strengthen its infrastructure and capabilities and reinforce its competitive position in key growth areas, including end-to-end AI transformation services.

Established in 1985, Samsung SDS is a leading provider of enterprise IT solutions. The Company delivers a comprehensive suite of services spanning cloud, digital transformation, artificial intelligence, and logistics to a global customer base across industries. As a core strategic priority, the Company continues to expand its AI transformation (AX) business through sustained investments in AI infrastructure, platforms, and capabilities. With approximately 26,000 employees and annual revenue of KRW 14 trillion, Samsung SDS combines scaled delivery capabilities with deep technical expertise and is well positioned to support its customers’ evolving needs for cloud adoption and digital transformation.

Chung Ho Park, Partner and Head of Korea at KKR, said, “This unique strategic partnership brings together Samsung SDS, part of one of Korea’s most established conglomerates, with KKR’s global experience in long-term value creation. Against a backdrop of increasing demand for digital transformation and AI solutions, we have strong conviction in Samsung SDS’ market leadership and growth potential by playing a critical role in advancing Korea’s digital capabilities and infrastructure. We look forward to leveraging KKR’s global network, deep local experience, and operational expertise to take the Company to its next stage of transformation as hands-on, active investors to drive long-term value creation for all shareholders and stakeholders.”

Jun Hee Lee, President and CEO of Samsung SDS, commented, “We are delighted to welcome KKR as a strategic investor as we continue to advance our growth strategy. Through this strategic collaboration, we will actively explore a wide range of growth opportunities, including M&A, by leveraging KKR’s expertise accumulated in global capital markets. Through cooperation between the two companies, we will continue to work closely together to enhance Samsung SDS’ corporate value and strengthen its foundation for global growth.”

KKR is making this investment primarily from its Asia Fund IV. This investment builds on KKR’s long-standing track record of investing in leading Korean companies with recent examples including Samhwa, MUSINSA, HD Hyundai Marine Solution, and SK Eternix. It also adds to KKR’s experience in the IT services sector globally, including FUJI SOFT, a leading system integrator in Japan; DATAGROUP, a leading IT solutions provider in Germany; a global full-lifecycle digital services transformation company Ness Digital Engineering; Devoteam, an IT and cloud services company focused on enabling digital transformation in France; and leading hybrid IT services provider Ensono in the US.

The transaction is expected to close during the second quarter, subject to customary closing conditions. Additional details of the transaction were not disclosed.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

About Samsung SDS

Founded in 1985, Samsung SDS is an ICT company with solutions which have been leading the digital transformation and innovation of clients for over 30 years across a wide range of industries. With operations in more than 40 countries, Samsung SDS’ solutions utilize advanced analytics platforms, AI, blockchain, cloud technologies to serve a diverse range of industries including financial services, smart manufacturing, global logistics, and retail.

Media Contacts

For KKR:

Wei Jun Ong
+65 6922 5813
WeiJun.Ong@kkr.com

James Jarman
+65 8870 6452
James.Jarman@kkr.com

For Samsung SDS:

pr_sds@samsung.com
+82 2 6155 1026

Source: KKR

 

Download PDF

Categories: News

Tags: